• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, November 19, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Psychiatric Inpatient Study Links Elevated D-Dimer to Age and Specific Medications

by
November 19, 2026
in Health
Reading Time: 7 mins read
0
Psychiatric Inpatient Study Links Elevated D-Dimer to Age and Specific Medications

Psychiatric Inpatient Study Links Elevated D-Dimer to Age and Specific Medications

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A comprehensive retrospective observational study evaluating routine admission laboratory screenings across more than 10,000 psychiatric hospital admissions has revealed that abnormal D-dimer elevations occur in more than one in five individuals upon entering inpatient care. The investigation demonstrated that elevated circulating levels of this fibrin degradation product reflect a complex, multidimensional physical health profile rather than serving as an isolated signal of acute thrombosis or an intrinsic consequence of psychiatric psychiatric illness itself. Instead of aligning with specific diagnostic psychiatric classifications such as schizophrenia or mood disorders, variations in D-dimer were robustly driven by patient chronological age, widespread multi-system laboratory indicators of systemic inflammation and tissue injury, and active medication orders for specific psychotropic agents, notably olanzapine, lithium, and valproate. These findings illuminate the clinical and biochemical context surrounding incidental laboratory abnormalities in psychiatric wards, offering clinicians an empirical framework to interpret biomarker elevations without defaulting to diagnostic overreaction or unwarranted clinical dismissals.

D-dimer represents a soluble protein fragment generated when cross-linked fibrin is cleaved by plasmin during the physiological breakdown of blood clots. In conventional emergency and acute medical settings, testing for circulating D-dimer serves as a well-established negative predictive screening tool to exclude deep vein thrombosis and pulmonary embolism in patients categorized as presenting with low or moderate pre-test clinical probability. However, because fibrin formation and degradation are non-specific responses to endothelial disruption, tissue damage, and immune activation, elevated circulating levels regularly manifest across a wide spectrum of non-thrombotic medical circumstances. Advanced age, systemic infectious or inflammatory states, physiological trauma, surgical recovery, malignant neoplasms, hepatic dysfunction, renal impairment, and acute psychological or somatic stress can each drive substantial D-dimer elevations. In acute psychiatric facilities, evaluating venous thromboembolism risk and deciphering abnormal laboratory values is further complicated by severe psychiatric symptoms, motor agitation, prolonged physical inactivity, sedating pharmacotherapy, mechanical restraint, and compromised patient capacity to perceive or communicate physical symptoms.

To rigorously characterize the clinical and pharmacological correlates of abnormal D-dimer measurements in routine psychiatric practice, researchers analyzed admission records from a major tertiary psychiatric hospital in Beijing, China, spanning from August 2018 through October 2019. Because the participating institution mandated routine D-dimer screening as a standard component of its baseline admission laboratory protocol, testing was conducted systematically across all admitted individuals rather than being restricted to instances of overt thromboembolic suspicion. The primary analytical cohort encompassed 10,211 distinct hospital admissions contributed by 9,320 unique individual patients, representing an aggregate dataset of 12,310 D-dimer testing events. The patient cohort had a mean age of 37.79 years with a standard deviation of 16.34 years, and female patients accounted for 5,947 admissions, or 58.24 percent of the total sample. Testing was performed on a Sysmex CS2000i coagulation analyzer utilizing Siemens INNOVANCE particle-enhanced immunoturbidimetric reagents, defining abnormal elevation above a clinical upper reference limit of 0.55 milligrams per liter in fibrinogen equivalent units.

Across the complete admission cohort, 2,100 admissions, representing 20.57 percent of the screened population, exhibited elevated D-dimer levels exceeding the clinical threshold, with an overall median concentration of 0.250 milligrams per liter and an interquartile range of 0.095 to 0.470 milligrams per liter. The frequency of elevated results demonstrated an exceptionally sharp gradient across age strata. While abnormal concentrations were observed in only 10.44 percent of patients younger than 18 years of age and 18.13 percent of adults aged 18 to 60 years, the prevalence surged to 48.66 percent among individuals older than 60 years. Multivariable modeling treating age as a continuous variable confirmed this striking age dependence, showing that each 10-year increment in age was associated with an odds ratio of 1.494 for binary D-dimer elevation and a geometric mean ratio of 1.213 for log-transformed continuous D-dimer concentrations. Conversely, after adjusting for chronological age, patient sex exhibited no statistically significant relationship with D-dimer elevation, yielding an odds ratio of 1.009. Furthermore, standardized primary psychiatric diagnostic categories did not exhibit independent associations with D-dimer outcomes once age and sex were accounted for in multivariable models.

To explore the broader somatic environment accompanying altered coagulation profiles, the investigators prespecified and evaluated 24 unique routine laboratory indicators captured concurrently on the exact date of D-dimer sampling, categorizing them across five core clinical domains: inflammation, coagulation balance, hepatic and renal function with tissue injury, lipid metabolism, and endocrine signaling. Following univariable screening of all 24 candidates across continuous, binary, and ordinal four-level severity outcomes, an exploratory integrated multivariable model was constructed using complete-case data from 6,507 testing events, including 1,148 cases with elevated D-dimer. This integrated model simultaneously adjusted for age, sex, primary psychiatric diagnosis, and twelve representative biochemical markers: C-reactive protein, erythrocyte sedimentation rate, fibrinogen, activated partial thromboplastin time, lactate dehydrogenase, aspartate aminotransferase, creatine kinase, serum triglycerides, low-density lipoprotein cholesterol, serum cortisol, prolactin, and progesterone.

The integrated multivariable analysis established that markers of systemic inflammation and cellular injury were independently and consistently associated with higher D-dimer values across all operational outcome definitions. Elevated C-reactive protein and accelerated erythrocyte sedimentation rate both demonstrated stable positive relationships with D-dimer levels, underscoring the intimate physiological crosstalk connecting inflammatory signaling pathways, vascular endothelial activation, and secondary fibrinolysis. Similarly, serum lactate dehydrogenase, a ubiquitous intracellular enzyme released into circulation following cellular damage, showed a highly consistent positive association with D-dimer across primary and sensitivity analyses. In contrast, activated partial thromboplastin time demonstrated an inverse association with D-dimer outcomes, where shorter clotting intervals correlated with greater D-dimer elevations, reflecting heightened procoagulant baseline activity. Serum triglyceride concentrations also exhibited an inverse relationship with D-dimer measurements across models, while biomarkers such as aspartate aminotransferase, creatine kinase, and cortisol failed to demonstrate stable, reproducible associations.

Endocrine indicators yielded particularly noteworthy contextual patterns, highlighted by a robust positive association between circulating serum prolactin concentrations and D-dimer outcomes that persisted across multiple sensitivity scenarios. Prolactin secretion is governed by hypothalamic-pituitary pathways and is known to surge in response to physiological stress, neuroendocrine alterations, and particularly pharmacological dopamine D2 receptor blockade induced by antipsychotic pharmacotherapy. Elevated prolactin has previously been hypothesized to influence platelet reactivity and vascular dynamics, and its stable co-occurrence with elevated D-dimer emphasizes that endocrine disruption constitutes a prominent component of the inpatient somatic environment. However, because direct causal hormonal mechanisms were not experimentally isolated, the study authors emphasized that prolactin should be regarded as a composite clinical indicator reflecting psychiatric distress, neuroendocrine regulation, and medication-induced receptor antagonism rather than definitive proof of a direct prothrombotic hormonal cascade.

Pharmacological analyses evaluated active medication orders recorded on the specific date of blood sampling, classifying agents by broad therapeutic class, predominant neuropharmacological mechanism, and individual chemical identity. At the broad class level, psychotropic categories failed to exhibit uniform effects, demonstrating that class labels alone obscure divergent compound-specific behaviors. Antidepressants, anxiolytics, sedatives, hypnotics, and cognitive enhancers showed no stable or statistically significant associations with D-dimer parameters. However, mood-stabilizing agents and ion-channel modulators demonstrated significant negative associations with D-dimer. When disaggregated into individual medications, distinct pharmacological profiles emerged: active orders for lithium and valproate were independently associated with significantly lower D-dimer concentrations and lower odds of elevation, whereas active orders for the second-generation antipsychotic olanzapine were associated with significantly higher D-dimer levels. These individual medication associations remained robust and statistically significant after applying Benjamini-Hochberg false discovery rate corrections and adjusting for the twelve representative laboratory biomarkers.

To explore whether these observed pharmacological associations reflected direct pharmacological mechanisms or broader clinical and biological confounding, the researchers examined prescribed daily dosages, therapeutic drug monitoring serum concentrations, and repeated testing events analyzed via generalized estimating equations. Crucially, these detailed analyses revealed an absence of stable, reproducible dose-response or concentration-response relationships for olanzapine, lithium, or valproate. Although lithium serum concentrations exhibited a nominal negative correlation with log-transformed D-dimer levels, the association narrowly missed the prespecified statistical significance threshold after false discovery rate adjustment. The absence of linear biological dose-response patterns indicates that the observed associations cannot be interpreted as simple direct pharmacological causation. Instead, the higher D-dimer levels observed in patients prescribed olanzapine likely reflect a complex constellation of treatment-associated metabolic disturbances, weight gain, profound sedation, reduced physical mobilization, and pre-existing cardiovascular risk profiles. Conversely, valproate-associated reductions may relate to known hemostatic effects on primary platelet function, while lithium signals may reflect specialized clinical monitoring and distinct patient stabilization trajectories.

The investigators further scrutinized their findings through multiple rigorous sensitivity and supplementary analyses, testing alternative replacement values for sub-threshold D-dimer measurements, stratifying records by chronological age groups, evaluating all 12,310 testing events, and excluding records with severe D-dimer elevations exceeding 4.00 milligrams per liter. The core associations identified for lactate dehydrogenase, activated partial thromboplastin time, prolactin, and inflammatory markers remained entirely stable following the exclusion of severe elevations, verifying that the results were not artifacts driven by a tiny subset of extreme outliers. In a supplementary analysis evaluating 7,462 testing events with available body mass index measurements, body mass index was inversely associated with D-dimer levels after controlling for age, sex, and diagnosis, a surprising finding that diverged from typical community-based cohorts. Nevertheless, incorporating continuous body mass index adjustment into multivariable medication models produced negligible shifts in effect sizes and did not alter the direction or significance of the associations observed for olanzapine, lithium, or valproate.

Several methodological and structural limitations must be considered when contextualizing the study conclusions. Because the investigation relied upon a single-center retrospective observational design utilizing historical electronic health records from one specialized tertiary psychiatric institution, the observed statistical patterns describe clinical correlations and cannot establish definitive biological causality or clinical generalizability to general hospital wards where testing occurs selectively. Furthermore, medication exposure was operationalized solely through active electronic physician orders on the sampling date or within an event-linked 14-day pre-sampling window, which captures recorded prescription intent rather than verifying actual oral ingestion, patient compliance, or systemic absorption. Electronic records also exhibited limited documentation of underlying somatic comorbidities, acute infectious episodes, physical restraint episodes, detailed immobilization durations, and confirmed radiological thromboembolic diagnoses. Finally, relying on complete-case analyses for the twelve-variable laboratory model resulted in sample attrition without multiple imputation, and ordinal regression proportional odds assumptions were not systematically validated across every outcome tier.

Ultimately, this extensive real-world investigation demonstrates that elevated D-dimer in psychiatric inpatients is a frequent, multifactorial laboratory phenomenon deeply embedded within the patient’s overall physiological and pharmacological status. Rather than treating an isolated abnormal result as definitive evidence of an acute thrombotic occlusion or reflexively attributing it to generic psychotropic drug exposure, clinicians must interpret D-dimer values through a structured, context-sensitive lens. Clinicians evaluating an elevated D-dimer finding should integrate patient chronological age, physical immobility, mechanical restraint history, concurrent signs of systemic inflammation or tissue injury, and specific pharmacotherapy into their diagnostic reasoning. By recognizing how age, inflammatory markers, cellular stress, and specific medications converge to influence coagulation markers, psychiatric and medical teams can avoid both premature diagnostic closure and unnecessary invasive interventions, thereby delivering balanced, targeted physical health surveillance throughout inpatient hospitalization and long-term psychiatric rehabilitation.

Subject of Research: Clinical, laboratory, and psychotropic medication correlates of abnormal D-dimer levels in psychiatric inpatients

Article Title: Clinical and psychotropic medication context of abnormal D-dimer results in psychiatric inpatients: a retrospective observational study

Article References: Qi, X., He, J., Guo, Q., Xue, X., Ling, S., & Liu, C. (2026). Clinical and psychotropic medication context of abnormal D-dimer results in psychiatric inpatients: a retrospective observational study. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08882-5

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08882-5

Keywords: D-dimer, Psychiatric Inpatients, Venous Thromboembolism, Psychopharmacology, Olanzapine, Lithium, Valproate, C-Reactive Protein, Erythrocyte Sedimentation Rate, Lactate Dehydrogenase, Activated Partial Thromboplastin Time, Prolactin, Therapeutic Drug Monitoring, Coagulation Biomarkers, Inpatient Medicine, Retrospective Cohort

News Source: Glenn Wilkins. (November 19, 2026). Psychiatric Inpatient Study Links Elevated D-Dimer to Age and Specific Medications. Scienmag.

Tags: activated partial thromboplastin timeC-reactive proteincoagulation biomarkersD-dimererythrocyte sedimentation rateInpatient Medicinelactate dehydrogenaselithiumolanzapineprolactinpsychiatric inpatientspsychopharmacologyRetrospective Cohorttherapeutic drug monitoringvalproatevenous thromboembolism
Share12Tweet7Share2ShareShareShare1

Related Posts

Cumulative Moderate Heat Exposure Across Life Linked to European Memory Decline

Cumulative Moderate Heat Exposure Across Life Linked to European Memory Decline

November 19, 2026
Maternal Oral Health Links to Childhood Allergic Rhinitis and Food Allergy Risk

Maternal Oral Health Links to Childhood Allergic Rhinitis and Food Allergy Risk

November 19, 2026

Dental Reform Significantly Increases Access for Older Adults in Israel

November 19, 2026

Thai National Survey Finds Financial Barriers Constrain Antidepressant Prescribing Choices

November 19, 2026

POPULAR NEWS

  • Mouse Study Maps Chromatin and Splicing Shifts Driving Sertoli Cell Maturation

    Mouse Study Maps Chromatin and Splicing Shifts Driving Sertoli Cell Maturation

    29 shares
    Share 12 Tweet 7
  • Meta-Analysis Identifies Major Factors Shaping Clinical Healthcare Provider Performance

    29 shares
    Share 12 Tweet 7
  • Layered Double Hydroxide Nanomaterials Advance Targeted Drug Delivery Across Biomedical Applications

    29 shares
    Share 12 Tweet 7
  • Lovastatin and 1-MCP Suppress Scald Genes in Cold-Stored Apples

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Cumulative Moderate Heat Exposure Across Life Linked to European Memory Decline

Bearing Control Coordinates Unicycle Robots Despite Unknown Leader Velocities

Exclusive Semi-Leptonic Decays Constrain b Hadron Production Ratios at LHC

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.